The UK and US have reached a important trade agreement that will keep no tariffs on UK medicine products going into the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has pledged to increase spending on medicines through the public health system. This commitment ensures that tariffs on these crucial products will be held at nothing for a duration of 36 months.
This agreement follows earlier threats to significantly raise import taxes on patented drug products, with increases floated up to one hundred percent.
"This agreement with the United Kingdom reinforces the worldwide climate for new treatments and brings much-needed fairness to transatlantic drug exports," an announcement noted.
Trade Impact
Medicines represent one of the UK's biggest export categories to the America, which is easily the primary destination for large companies like GSK and AstraZeneca.
Export figures reveal that in the year leading up to last September, the UK sold medicines worth £11.1bn to the US. This value accounted for a significant portion of all goods exports in that period.
"This agreement protects employment, stimulates investment and sets the stage for the UK to establish itself as a global hub for medical research," the Business and Trade Secretary commented.
Key British Pledges
The deal includes several notable changes from the British government:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it judges new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a aim to double overall NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum manufacturers must refund to the NHS to prevent overspending will be limited at fifteen percent. Last year, refunds exceeded 20%.
Recent Tensions
The deal follows a ongoing row between the sector and the ministers over drug pricing and approval rates.
The disagreement were intensified by arguments that American consumers were paying a premium for the equivalent treatments than patients in the Britain and the EU.
Recently, several large drug company projects in the UK have been paused or scrapped, while multi-billion-dollar funding commitments have been announced toward US facilities.
A senior figure stated that the NHS must invest a greater share on treatments, noting that its spending on drugs had decreased as a share of its resources over the previous ten-year period.
